Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Signs Distribution Agreement for Prostate Cancer Tests in Poland

NEW YORK (GenomeWeb) – Molecular diagnostics developer MDxHealth announced today it has signed a distribution agreement with The European Health Centre Innovation (EHC Innovation) for distribution of MDxHealth's two prostate cancer tests in Poland.

Under the terms of the agreement, EHC Innovation will distribute the SelectMDx for Prostate Cancer and ConfirmMDx for Prostate Cancer tests to its urology customers throughout the country. Samples will still be sent to MDxHealth's clinical diagnostic laboratory in The Netherlands for analysis, and EHC Innovation will reimburse MDxHealth for all testing services.

Further financial terms of the deal were not disclosed.

"We are delighted to announce our collaboration with The European Health Centre Innovation which, as part of European Health Center Otwock Hospital, is the most technologically advanced multispecialty diagnostic center in Poland," MDxHealth CEO Jan Groen said in a statement. "We believe that SelectMDx and ConfirmMDx perfectly complement EHC Innovation's existing portfolio of advanced diagnostic tools. With a strong reputation throughout the region and focus on improving patient care and outcomes, EHC Innovation is an ideal partner to help us raise awareness and expand access to SelectMDx and ConfirmMDx within the urology community."